Evidence map›Paper›PMID 26568059›Full record

ArticlePathogens and disease2016

TLR2, TLR4 and TLR9 genotypes and haplotypes in the susceptibility to and clinical course of Chlamydia trachomatis infections in Dutch women.

Stephan P Verweij, Ouafae Karimi, Jolein Pleijster, Joseph M Lyons, Henry J C de Vries, Jolande A Land, Servaas A Morré, Sander Ouburg

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens and disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Recognition ofInfection and immunity · 2024
    Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Stephan P VerweijLaboratory of Immunogenetics, Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam, 1081 HV, the Netherlands.
Ouafae KarimiLaboratory of Immunogenetics, Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam, 1081 HV, the Netherlands Department of Internal Medicine, VU University Medical Center, Amsterdam, 1081 HV, the Netherlands.
Jolein PleijsterLaboratory of Immunogenetics, Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam, 1081 HV, the Netherlands.
Joseph M LyonsLaboratory of Immunogenetics, Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam, 1081 HV, the Netherlands.
Henry J C de VriesSTI outpatient clinic, Cluster Infectious Diseases, Municipal Health Service Amsterdam, Amsterdam, 1018 WT, the Netherlands Department of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, 1105 AZ, the Netherlands National Institute for Public Health and the Environment, Bilthoven, 3721 MA, the Netherlands Department of Internal Medicine, Division of Infectious Diseases, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, Amsterdam, 1105 AZ, the Netherlands.
Jolande A LandDepartment of Obstetrics and Gynaecology, UMCG, University of Groningen, Groningen, 9713 GZ, the Netherlands.
Servaas A MorréLaboratory of Immunogenetics, Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam, 1081 HV, the Netherlands Institute of Public Health Genomics, Department of Genetics and Cell Biology, Research Institute GROW, Faculty of Health, Medicine & Life Sciences, University of Maastricht, Maastricht, 6229 ER, the Netherlands samorretravel@yahoo.co.uk.
Sander OuburgLaboratory of Immunogenetics, Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam, 1081 HV, the Netherlands.
Amsterdam UMC Location VUmc · NLAcademic Medical Center · NLMaastricht University · NLUniversity of Groningen · NL

Funding

Identifying Biomarkers and Genetic Risk Factors Predictive of Reproductive SequelR21AI098660 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DARVILLE, TONI · 2012 to 2013
$359k
NIAID NIH HHS 1R21AI098660-01
6 · The paper itself

Abstract

Chlamydia trachomatis infections demonstrate remarkable differences in clinical course that are approximately 40% based on host genetic variation. Here, we study the single nucleotide polymorphisms (SNPs) and their haplotypes in TLR2, TLR4 and TLR9 (TLR2 +2477G>A; TLR2 -16934T>A; TLR4+896A>G; TLR9 -1237T>C and TLR9 +2848G>A) in relation to the susceptibility to, and severity of C. trachomatis infections. We analysed the five SNPs in a cohort of 770 Dutch Caucasian women either attending a sexually transmitted diseases outpatient clinic (n = 731) or having complaints of subfertility (n = 39). Haplotype analyses showed a trend for TLR2 haplotype I (-16934T/+2477G) to protect against the development of symptoms and tubal pathology (Ptrend = 0.03) after Chlamydia infection. In the susceptibility cohort, TLR9 haplotype III (-1237C/+2848A) showed a significant decreasing trend in the development of symptoms after C. trachomatis infection (P = 0.02, OR: 0.55, 95%CI: 0.33-0.91). Logistic regression of the TLR2 haplotypes, TLR4+896A>G, and TLR9 haplotypes showed that the TLR2 haplotype combinations AG-TA and AG-TG confer risk (OR 3.4 (P = 0.01) and 1.6 (P = 0.03)), while the TLR9 haplotype combination TG-TA protects against C. trachomatis infections (OR: 0.4, P = 0.004). Our study shows that both TLR2 and TLR9 genes and SNP combinations do influence the clinical course of Chlamydia infections.

Indexed as

Genetic Predisposition to DiseasePolymorphism, Single NucleotideAdolescentAdultChlamydia trachomatisCohort StudiesFemaleHaplotypesHumansLymphogranuloma VenereumNetherlandsToll-Like Receptor 2Toll-Like Receptor 4Toll-Like Receptor 9White PeopleYoung AdultTLR2 protein, humanTLR4 protein, humanTLR9 protein, humanToll-Like Receptor 2Toll-Like Receptor 4Toll-Like Receptor 9Chlamydia trachomatisClinical outcomeImmunogeneticsToll-like receptors

Identifiers

PMID26568059
PMCPMC4882084
OpenAlexW2220141948

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.